UNITED THERAPEUTICS Business Summary

United Therapeutics Corporation (UTHR) operates as a biotechnology leader primarily focused on the development and commercialization of therapies for rare diseases, specifically pulmonary arterial hypertension (PAH). The company generates revenue through a high-margin pharmaceutical model, anchored by its treprostinil-based franchise which includes Tyvaso (nebulized and dry powder inhaler), Orenitram, and Remodulin. Its strategic growth is categorized into three "waves": the Foundation wave (current PAH commercial business), the Innovation wave (late-stage pipeline assets like Ralinepag), and the Revolution wave, which focuses on bioengineered organ manufacturing and xenotransplantation. As of early 2026, the company has transitioned into a Public Benefit Corporation, successfully launching clinical trials for its UKidney and UHeart xenotransplantation programs. United Therapeutics maintains a dominant position in the prostacyclin market but faces intense competition from Merck (Winrevair), Johnson & Johnson (Actelion), and Liquidia Corporation (Yutrepia), positioning itself as a diversified pioneer moving beyond traditional pharmaceuticals into organ engineering. The company is led by Founder, Chairperson, and CEO Martine Rothblatt, a polymathic executive who previously founded SiriusXM and was recently elected to the National Academy of Engineering for her leadership in satellite engineering and organ transplantation. The senior leadership team includes Michael Benkowitz (President and COO), James Edgemond (CFO and Treasurer), and Leigh Peterson (EVP of Product Development and Xenotransplantation), who oversees the firm's groundbreaking organ manufacturing initiatives. The Board of Directors is notably high-profile, featuring futurist Ray Kurzweil, former HHS Secretary Tommy Thompson, and bioelectronic medicine pioneer Kevin J. Tracey, who was appointed in January 2026. Institutional backing remains robust, with significant positions held by major investors such as Renaissance Technologies and Dimensional Fund Advisors, reflecting confidence in the company's dual-track strategy of pharmaceutical dominance and long-term organ supply revolution.